Trial Profile
A Phase II, Open-Label, Multicenter Study to Evaluate the Antitumor Efficacy of CO-1.01 for Infusion as Second-Line Therapy for Gemcitabine- Refractory Patients With Stage IV Pancreatic Adenocarcinoma and No Tumor hENT1 Expression.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine elaidate (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Clovis Oncology [CEASED]
- 15 Feb 2013 Status changed from suspended to discontinued, based on a Clavis Pharma media release.
- 13 Nov 2012 Status changed from active, no longer recruiting to suspended, as reported in a Clovis Oncology media release.
- 18 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.